An open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3326595 in participants with solid tumors and non-Hodgkin’s lymphoma

Trial Identifier: 204653
Sponsor: GlaxoSmithKline
Collaborator:
NA
Start Date: August 2016
Primary Completion Date: August 2023
Study Completion Date: August 2023
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, AB Edmonton, AB, Canada, T6G 1Z2
Canada, ON Ottawa, ON, Canada, K1H 8L6
Canada, ON Toronto, ON, Canada, M5G 1Z5
France Bordeaux, France, 33076
France Lyon Cedex 08, France, 69373
France Villejuif cedex, France, 94805
Netherlands AMSTERDAM, Netherlands, 1066 CX
Netherlands LEIDEN, Netherlands, 2333 ZA
Netherlands ROTTERDAM, Netherlands, 3015 GD
United States, CO Denver, CO, United States, 80218
United States, FL Miami, FL, United States, 33136
United States, NY New York, NY, United States, 10065
United States, TN Nashville, TN, United States, 37203
United States, TX Dallas, TX, United States, 75230
United States, TX San Antonio, TX, United States, 78229